阿托伐他汀对急性冠脉综合征患者血清MMP-2及TIMP-2的作用被引量：3

The effect of atorvastatin on serum level of matrix metalloproteinase-2 and tissue inhibitors of matrix metalloproteinase-2 in patients with acute coronary syndromes

下载PDF

导出

摘要目的:研究应用阿托伐他汀(atorvastatin)对急性冠脉综合征(acute coronary syndromes ACS)患者减少炎症反应、稳定斑块的作用。方法:选定ACS患者51例,稳定型心绞痛(SA)患者15例及正常对照组20例。随机将ACS患者分为阿托伐他汀治疗组(27例)和常规治疗组(24例),比较各组间血清基质金属蛋白酶-2(MMP-2)及金属蛋白酶组织抑制剂-2(TIMP-2)的水平变化。结果:ACS组与SA组及正常对照组之间血清MMP-2、TIMP-2及MMP-2/TIMP-2水平相比差异有统计学意义,两治疗组治疗后血清MMP-2、TIMP-2水平相比差异有统计学意义。结论:阿托伐他汀可降低ACS患者血清MMP-2水平,升高TIMP-2水平,减少冠状动脉粥样斑块基质成分的降解和炎症反应,从而起到稳定动脉粥样硬化斑块的作用。 Objective： To investigate the influences of atorvastatin on serum MMP-2, TIMP-2 and MMP-2/TIMP-2 levels of patients with acute coronary syndrome（ACS）. Methods： There were 51 patients with ACS and 15 patients with SA, Meanwhile, 20 cases of age matched control individuals were selected. Then 51 patients with ACS were randomly divided into two groups： Atorvastatin treatment group and regular treatment group. The serum level of MMP-2 and TIMP-2 were compared among all groups. Results： There was significant difference in serum level of MMP-2 and TIMP-2 between ACS group and SA group and control group. There was significant difference in serum level of MMP-2 and TIMP-2 between atorvastatin treatment group and regular treatment group after treatment. Conclusion： atorvastatin could decrease the breakdown of matrix collagen and reduce inflammatory reaction, and it might have a beneficial effect on steadying the plaque.

作者吴照科李凌张金盈王晶晶张金英于运福魏经汉

机构地区郑州大学第一附属医院心内科解放军第

出处《河南医学研究》 CAS 2006年第1期44-46,共3页 Henan Medical Research

关键词急性冠脉综合症基质金属蛋白酶-2 金属蛋白酶组织抑制剂-2 阿托伐他汀 ACS MMP-2 TIMP-2 atorvastatin

分类号 R781.341 [医药卫生—口腔医学]

引文网络
相关文献

参考文献5

1Davies MJ.Reactive oxygen species,metalloproteinases,and plaque stability[J].Circulation,1998,97(24):2382-2383.
2Hou G,Mulholland D,Gronska MA,et al.Type Ⅷ collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury[J].Am J Pathol,2000,156(2):467-476.
3The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med,1998,339(19):1349-1357.
4Fukumoto Y,Libby P,Rabkin E,et al.Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlibidemic rabbits [ J ].Circulation,2001,103 (7):993-999.
5Newby LK,Kristinsson A,Bhapkar MV,et al.Early statin initiation and outcomes in patients with acute coronary syndromes[J].JA-MA,2002,287 (23):3087-3095.